Biotech Anatara Lifesciences, which is working to treat diarrhoea in farm animals, is set to target markets in Europe and the US.
The biotech has raised $9 million from investors, with the funds going towards international registration and further development of Anatara's lead product, Detach.
Detach is a natural, non-antibiotic treatment for diarrhoea in pigs and other farm animals.
"The combined $9 million raised will allow Anatara to move into both Europe and the US markets in parallel, as well as target the larger Asian markets earlier than originally forecast," Anatara chairman Dr Mel Bridges said on Tuesday.
"We will also be investigating moving into other livestock such as poultry and calves whilst advancing development of Detach's use in humans."
Anatara raised $2 million through a share purchase plan, and $7 million from a share placement to professional investors.
Dr Bridges said the funds put Anatara in a secure position and would enable a global rollout of Detach upon receipt of regulatory approvals.
Detach is based on a natural extract from pineapple stems.
The company says the natural plant-based treatment will help address global concerns around the overuse of antibiotics in farm animals.
The results of a second field trial of Detach are expected in the third quarter of the 2015 calendar year.
Anatara expects Detach to be on sale in Australia within 12 months of lodging an application for regulatory approval.
The company says approval in Australia will open the opportunity to quickly register Detach for sale in major Asian markets.
Shares in Anatara were two cents lower at 85 cents at 1314 AEST.
Share
